Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression

Cancer Discovery

Volumn 3, Issue 3, 2013, Pages 294-307

  Wang, Yufang ^a   Velho, Sérgia ^a   Vakiani, Efsevia ^d   Peng, Shouyong ^b   Bass, Adam J ^b,c   Chu, Gerald C ^b,c   Gierut, Jessica ^a   Bugni, James M ^f   Der, Channing J ^g   Philips, Mark ^e   Solit, David B ^d   Haigis, Kevin M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3, 4 DIFLUOROBENZAMIDE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AZ 628; AZOXYMETHANE; BETA CATENIN; DOCUSATE SODIUM; MITOGEN ACTIVATED PROTEIN KINASE; N RAS PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL FRACTIONATION; COLITIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; EXPRESSION VECTOR; GENE MUTATION; GENE SILENCING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFLAMMATION; MOUSE; NONHUMAN; ONCOGENE N RAS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; COLITIS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; GTP PHOSPHOHYDROLASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84876064070     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0198     Document Type: Article

References (50)

1. Malumbres M, Barbacid M. RAS oncogenes: the fi rst 30 years. Nat Rev Cancer 2003; 3: 459-65.
2. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413.
3. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002; 1602: 23-45.
4. Lau KS, Haigis KM. Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer. Mol Cells 2009; 28: 315-20.
5. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specifi-city in lung cancer. Nat Genet 2008; 40: 1240-4.
6. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-8.
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. New Engl J Med 1988; 319: 525-32.
8. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010; 19: 157-63.
9. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-11.
10. Ehrhardt A, David MD, Ehrhardt GR, Schrader JW. Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Mol Cell Biol 2004; 24: 6311-23.
11. Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profi ling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood 2003; 102: 2581-92.
12. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126-35.
13. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ, et al. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fi brosarcoma and DLD-1 colon carcinoma cells. Oncogene 1999; 18: 1807-17.
14. Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 2005; 115: 65-73.
15. Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol 2000; 95: 2710-9.
16. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and infl ammationdriven tumor progression. Nat Prot 2007; 2: 1998-2004.
17. Keller JW, Haigis KM, Franklin JL, Whitehead RH, Jacks T, Coffey RJ. Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. Oncogene 2007; 26: 3051-9.
18. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995; 80: 533-41.
19. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. C ancer Cell 2009; 15: 103-13.
20. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
21. Yu H, Pardoll D, Jove R. STATs in cancer infl ammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
22. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-62.
23. Roy S, Plowman S, Rotblat B, Prior IA, Muncke C, Grainger S, et al. Individual palmitoyl residues serve distinct roles in H-ras traffi cking, microlocalization, and signaling. Mol Cell Biol 2005; 25: 6722-33.
24. Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 2003; 160: 165-70.
25. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16: 1924-37.
26. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-46.
27. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 989-1000.
28. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
29. Terzic J, Grivennikov S, Karin E, Karin M. Infl ammation and colon cancer. Gastroenterology 2010; 138: 2101-14.
30. Borner C, Schlagbauer Wadl H, Fellay I, Selzer E, Polterauer P, Jansen B. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res 1999; 9: 347-50.
31. Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA. Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol 2002; 119: 556-61.
32. Wolfman JC, Wolfman A. Endogenous c-N-Ras provides a steadystate anti-apoptotic signal. J Biol Chem 2000; 275: 19315-23.
33. Wolfman JC, Palmby T, Der CJ, Wolfman A. Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. Mol Cell Biol 2002; 22: 1589-606.
34. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin J A, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006; 66: 9483-91.
35. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011; 117: 2022-32.
36. Tsuruma R, Ohbayashi N, Kamitani S, Ikeda O, Sato N, Muromoto R, et al. Physical and functional interactions between STAT3 and KAP1. Oncogene 2008; 27: 3054-9.
37. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002; 277: 37169-75.
38. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 34922-30.
39. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005; 65: 7292-300.
40. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modifi cation of RAS. Nat Rev Mol Cell Biol 2011; 13: 39-51
41. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
42. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identifi cation of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-5.
43. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profi les. Proc Natl Acad Sci USA 2005; 102: 15545-50.
44. TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
45. Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 2010; 138: 1003-11 e1-5.
46. el Marjou F, Janssen KP, Chang BH, Li M, Hindie V, Chan L, et al. Tissue-specifi c and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004; 39: 186-93.
47. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260: 85-8.
48. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-5.
49. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, et al. Oncogenic Ras activation of Raf/ mitogen-activated protein kinase-independent pathways is suffi-cient to cause tumorigenic transformation. Mol Cell Biol 1996; 16: 3923-33.
50. Macdonald JL, Pike LJ. A simplifi ed method for the preparation of detergent-free lipid rafts. J Lipid Res 2005; 46: 1061-7.